Shares in Phylogica Limited
(ASX:PYC) surged almost 85 per cent yesterday after reporting a cancer pilot study success.
The drug discovery group says its peptide fusions have been shown to kill aggressive, drug-resistant breast cancer cells.
The company also advises its phylomer peptide fusions have been shown to significantly boost the potency of cancer drugs.
Phylogica says it was not expecting such a striking result from the pilot study and has described the findings as a potential paradigm shift for cancer therapeutics.
Phylogica reported a net loss of $135,000 in the first half of the 2015 financial year.
